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We report the first case of community-acquired bac-
teremia with Burkholderia fungorum, a newly described
member of the Burkholderia cepacia complex. A 9-year-old
girl sought treatment with septic arthritis in her right knee
and ankle with soft tissue involvement. Commercial identifi-
cation systems did not identify the causative microorganism.
T
he genus Burkholderia contains >30 species, of which
Burkholderia pseudomallei, B. mallei, and members of
the  B. cepacia complex are the most well known. The
species  B. fungorum was recently proposed for isolates
recovered from the environment, and animal and human
clinical samples (1,2). Here we describe the first case of
community-acquired bacteremia with B. fungorum in a 9-
year old girl with the clinical features of septic arthritis. 
Case Report
Apreviously healthy 9-year-old girl had pain, swelling,
and redness of the right foot and ankle 4 days before hos-
pital admission, and similar symptoms of the right knee, 2
days before admission. One day before admission, a tem-
perature of 39°C developed. She and her family had no
history of arthritis, rheumatic arthritis, or other autoim-
mune disorders.
On physical examination, she had a body temperature
of 38.8°C. Except for some slight swelling, pain, and red-
ness of the right ankle, no other abnormalities or suspect-
ed source of the fever was apparent. She did not allow
pressure on the calcaneus, which was painful.
Laboratory investigations demonstrated a C-reactive
protein level of 262 mg/L, an erythrocyte sedimentation
rate of 125 mm in the first hour, and a leukocyte count of
12.6 × 109/L with 9.1 × 109/L neutrophils. Levels of serum
electrolytes, creatinine, and hepatic enzymes were within
normal limits. Tests for antinuclear antibodies and antineu-
trophilcytoplasmic antibodies were negative. Serologic
results for cytomegalovirus, Toxoplasma gondii, Borrelia
burgdorferi, and Epstein-Barr virus were unremarkable.
Throat and feces samples were negative for any virus.
Feces cultures were negative for Salmonella,  Shigella,
Yersinia, and Campylobacter. 
Radiologic examination of the right lower leg demon-
strated no abnormalities of knee, foot, and ankle. A mag-
netic resonance imaging scan of the right lower leg showed
a modest fluid collection in the soft tissues between the
calcaneus and fascia plantaris, but no signs of
osteomyelitis. An echogram of the abdomen was unreveal-
ing, and a computed tomographic scan of the cerebrum
showed no signs of an intracranial or sinus infection.
A bone scintigraph demonstrated a slight asymmetric
increased signal in the epiphysial disc of the femur at the
right knee. Because osteomyelitis with soft tissue involve-
ment was suspected, she was empirically treated with intra-
venous cefuroxime (800 mg 3x/day), which was continued
when the blood cultures became positive with gram-nega-
tive rods (on the fourth day of admission). Defervescence
was initially seen within 24 h, but her temperature rose
again to 38.5°C on the day 3 and up to 40.5°C on the day 7
of antimicrobial therapy. Because the cultured gram-nega-
tive rod was susceptible to cefuroxime in vitro, antimicro-
bial treatment was not changed. C-reactive protein level
initially diminished gradually to 162 mg/L, but increased to
310 mg/L. Several diagnostic efforts, including a cardiac
echogram, electrocardiogram, and an ear, nose, and throat
workup, were carried out to determine the focus of infec-
tion but without convincing results. Although the patient
had a clinical course of recurrent fever, she was otherwise
stable, and we therefore decided to discontinue cefuroxime
on day 9. At that time, the gram-negative rods in blood cul-
tures, obtained before and during cefuroxime treatment,
were reported to be B. fungorum. Intravenous
ciprofloxacin, 170 mg 2x/day (15 mg/kg/day), was started;
within 24 h, she became afebrile, and the C-reactive protein
level became normal within 1 week. After 10 days, intra-
venous administration of ciprofloxacin was changed to oral
administration (180 mg 2x/day) and continued for another
4 weeks. She recovered completely without sequelae.
On 3 following days, before and during treatment with
cefuroxime, 5 blood cultures were collected in BACTEC
aerobic pediatric resin bottles (Becton Dickinson, Sparks,
MD, USA) and incubated in the BACTEC 9240 (Becton
Dickinson). All blood cultures yielded gram-negative rods
after 4 days of incubation. Subcultures produced a fine
growth after 1 day of incubation.
The organism was positive for catalase and oxidase,
and routine identification procedures with the API 20NE
kit and database release 6.0 (bioMérieux, Marcy l’Etoile,
France) produced the numerical code profile 1066157
which, according to the database, was a good identification
(98.9% T 0.42) as B. cepacia. Antimicrobial susceptibility
testing was performed with broth microdilution in accor-
dance with Clinical and Laboratory Standards Institute
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*Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands; †Sint
Maartenskliniek, Ubbergen, the Netherlands; and ‡University of
Ghent, Ghent, Belgium(formerly NCCLS) protocols (3). The organism was sus-
ceptible to amoxicillin (MIC 1 mg/L), cefotaxime (MIC
0.5 mg/L), ceftazidime (MIC <0.5 mg/L), cefuroxime
(MIC 1 mg/L), trimethoprim/sulfamethoxazole (MIC <1
mg/L), meropenem (MIC 0.25 mg/L), tobramycin (MIC
<0.25 mg/L), and ciprofloxacin (MIC 0.5 mg/L), but
resistant to cefazolin (MIC >32 mg/L). This rather suscep-
tible microorganism prompted us to repeat the identifica-
tion with partial sequencing of the 16S rRNA gene. DNA
was isolated from a pure culture by using established pro-
tocols (4). Amplification primers 5′-CCTAACACATG-
CAAGTCGARCG-3′ (forward) and 5′-CGTAT-TACCG-
CGGCTGCT-3′ (reverse), both from Eurogentec (Seraing,
Belgium) were used in a standard polymerase chain reac-
tion (PCR) to generate a 490-bp fragment from the 5′ end
of the 16S gene. The PCR (25 µL) consisted of 1 µLDNA,
0.5 µmol/L of both PCR primers, 1.5 mmol/L MgCl2, 0.2
mmol/L dNTP, and 1 U FastStart Taq DNA polymerase
(Roche Diagnostics, Almere, the Netherlands) in 1 x reac-
tion buffer. Cycling conditions were as follows: 30 s at
94°C, 30 s at 56°C, and 1 min at 72°C, repeated 30 times,
preceded by a 10-min activation step at 94°C and followed
by an additional 10 min elongation step at 72°C. The
obtained amplicon was purified by using High Pure chem-
istry (Roche Diagnostics) and sequenced with the reverse
amplification primer using a MegaBACE DYEnamic ET
Dye terminator Kit as suggested by the manufacturer
(Amersham Biosciences, Roosendaal, the Netherlands).
Reaction products were purified by ethanol precipitation,
dissolved in distilled water, and analyzed on a MegaBACE
500-capillary DNA analysis platform (Amersham
Biosciences) under standard electrophoretic conditions.
The obtained DNA sequence was compared to the public
DNA databases by using the BLAST interface
(http://www.ncbi.nlm.nih.gov/BLAST/) (5) and proved to
be 100% identical to previously reported B. fungorum
sequences.
To confirm this molecular identification, cellular pro-
tein and fatty acid analyses were also performed. Whole-
cell proteins were prepared and evaluated with sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (1).
The identification of the isolate as B. fungorum was subse-
quently confirmed by comparing it to a large database,
which contained profiles of all Burkholderia, Ralstonia,
and Pandoraea species and various other gram-negative
nonfermenters (2). After aerobic growth for 24 h on
Trypticase soy agar (Becton Dickinson, Erembodegem,
Belgium), a loopful of well-grown cells was harvested, and
fatty acid methyl esters were prepared, separated, and
identified by using the Microbial Identification System
(MIDI, Inc., Newark, DE, USA). By using the commer-
cially available database (MIDI, Inc.), the isolate was
again falsely identified as B. cepacia with a score of 0.611.
The oxidase-positive isolate reduced nitrate and assim-
ilated glucose, mannose, mannitol, N-acetyl-glucosamine,
adipate, malate, citrate, and caprate. Beta-galactosidase
activity was present.
Conclusions
To the best of our knowledge, this case is the first
description of bacteremia and invasive infection due to B.
fungorum. The name B. fungorum was recently proposed
for a group of 9 B. cepacia–like isolates recovered from
the environment and human and animal clinical samples
(1). The only 2 strains from human clinical samples in that
study were recovered from the vaginal secretions of a
pregnant woman (22 weeks) with Candida sp. vaginitis
and preterm labor, and the cerebrospinal fluid of a 66-year-
old woman, respectively. No clinical data were available
from these patients; therefore, the clinical significance
could not be determined. Since the original report was
made, B. fungorum has been identified in a range of soil-
and plant-associated samples, in infections of the central
nervous system of a pig and a deer (H. Scholz and P.
Vandamme, unpub. data), and in the respiratory secretions
of people with cystic fibrosis (1,2). However, in these
cases, the clinical significance of isolation of B. fungorum
was also unclear. 
Since B. fungorum was only described recently and has
not been found frequently in clinical samples, the organism
is not included in most commercial biochemical databases
used for identification, and it has previously been shown
that B. fungorum isolates can easily be misidentified as B.
cepacia complex organisms (1,2). A similar misidentifica-
tion with conventional commercial biochemical tests was
recently described in a case of B. cenocepacia vaginal
infection (6). In the present case, the antimicrobial suscep-
tibility profile, the patient’s history, and the clinical findings
suggested that this isolate did not belong to the B. cepacia
complex, and the identification as B. fungorum was con-
firmed by using a polyphasic approach. Most B. cepacia
complex infections in non–cystic fibrosis patients are noso-
comial in origin, but severe community-acquired infections
(including endocarditis, brain abscesses, and pneumonia)
have also been reported (7). As this case illustrates, B. fun-
gorum may pose a challenge to many clinical microbiology
laboratories, and infections with this organism may be erro-
neously diagnosed as B.  cepacia complex infections. A
complete immunologic workup for our patient did not give
any indication of why this child experienced this infection.
The source of the B. fungorum bacteremia in our patient
remained elusive, but, undoubtedly, it was a community-
acquired infection manifested as a soft tissue infection of
her leg. Of interest was the clinical failure of cefuroxime
therapy, despite the isolate’s in vitro susceptibility, and the
rapid response to ciprofloxacin treatment. 
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